

PUF Ventures Appoints Tim McNulty as Senior Investor Relations Advisor

VANCOUVER, March 10, 2017 /CNW/ - **PUF Ventures Inc.** (the "**Company**") (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF) is pleased to announce that Mr. Tim McNulty has been appointed senior investor relations advisor to the Company. Mr. McNulty is a seasoned investor relations and corporate finance consultant with over 15 years' experience executing value enhancing financial strategies for large and small public companies listed on the NYSE, TSX and/or TSX Venture stock exchanges. He has extensive financial market knowledge coupled with experience in corporate development, investor relations and capital raising mandates.

"We are pleased to welcome Tim to PUF to assist us in all aspects of our investor relations and corporate finance strategy," said Derek Ivany, President and CEO of the Company. "As we continue building out our management team in anticipation of receiving an Access to Cannabis for Medical Purposes Regulations (ACMPR) license we believe Tim will immediately add value in enhancing our shareholder communication capabilities. Investor engagement is very important to PUF as we navigate this exciting and high growth, nascent industry. While the timing of a final ACMPR license remains unclear, our goal is to become a leading supplier of medical cannabis in Canada. As a public market specialist, we look to Tim's experience to position the Company as a leader in the emerging industry of Medical and Recreational Cannabis production."

Administrative Update

Further to PUF's commitment to building a leading Cannabis brand, the Company has secured the domain "www.PUF.ca" as a landing page for the corporate website and for future potential marketing initiatives. A detailed brand positioning exercise is currently underway and is being spearheaded by a strategic development group in Toronto, Ontario.

Further, shareholders and interested parties alike are encouraged to take note of PUF's new corporate contact co-ordinates: 1-800-PUF-6056.

About PUF Ventures Inc.

PUF Ventures is moving into the biomedical cannabis sector by purchasing a 100-per-cent interest in AAA Heidelberg, a private Ontario company that is currently in Stage 5 of 7 in its application for an ACMPR (access to cannabis for medical purposes regulations) license. VapeTronix, a subsidiary of the company, is in the process of expanding its 1313 brand of electronic cigarettes, marijuana vape delivery devices and associated technologies.

ON BEHALF OF THE BOARD OF DIRECTORS

Derek Ivany
President & CEO

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

SOURCE PUF Ventures

To view the original version on PR Newswire, visit: <http://www.newswire.ca/en/releases/archive/March2017/10/c3977.html>

%SEDAR: 00022839E

For further information: Tim McNulty, Phone: 1 (800) 783 - 6056 Ext. 3, Email: IR@PUF.CA; Suite 804 - 750 West Pender Street, Vancouver, BC, V6C 2T7, T: (800) 783-6056 / F: (604) 685-6905 / W: www.puf.ca

CO: PUF Ventures

CNW 17:08e 10-MAR-17